- ►diabetesjournals.org C Saloranta, C Guitard, E Pecher, P de Pablos … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—This multicenter, double-blind, randomized,
parallel-group, fixed-dose study of 8 weeks' duration was performed in a total
of 288 subjects with IGT using a 2:2:2:1 randomization. Subjects received ... Cited by 34 - Related articles - BL Direct - All 11 versions
[CITATION] Acabose for prevention of type 2diabetes mellitus: the STOP-NIDDM randomized trial
VA Fonseca, DE Kelley, W Cefalu, MA Baron, D … - Metabolism, 2004 - Elsevier Antidiabetic agents that augment insulin secretion can cause hypoglycemia. With
the current trend toward early and aggressive treatment of patients with type 2
diabetes, the hypoglycemic potential of insulinotropic agents is of ... Cited by 12 - Related articles - All 9 versions
- ►endojournals.org C Saloranta, K Hershon, M Ball, S Dickinson, … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Nateglinide is a fast-acting insulin secretion agent that specifically targets
postprandial hyperglycemia in patients with type 2 diabetes. The recent
reduction in the diagnostic criteria for diabetes and improved ... Cited by 43 - Related articles - BL Direct - All 6 versions
RE Pratley, JE Foley, BE Dunning - Current pharmaceutical design, 2001 - ingentaconnect.com Abstract: The loss of early insulin secretion appears to be a critical event in
the deterioration in glucose tolerance during the development of type 2
diabetes. There is therefore a strong rationale for developing new ... Cited by 17 - Related articles - BL Direct - All 3 versions
- ►pharm.or.jp [PDF] T Mine, K Miura, Y Kitahara, A Okano, R … - Biological & pharmaceutical bulletin, 2002 - J-STAGE Recent epidemiological studies have shown that postprandial triglyceride levels,
as well as postprandial glucose levels, are an important contributing factor to
development of athero- sclerosis and cardiovascular disease. 3—5) ... Cited by 17 - Related articles - BL Direct - All 6 versions
ES Horton, JE Foley, SG Shen, MA Baron - Current Medical Research and Opinion®, 2004 - informahealthcare.com Objective: To assess the efficacy and tolerability of the combination of
nateglinide (120 mg, ac) and metformin (500 mg, tid) as initial treatment in
drug-naïve patients with type 2 diabetes mellitus (T2DM). Research design ... Cited by 19 - Related articles - BL Direct - All 7 versions
J Vakkilainen, N Mero, A Schweizer, JE … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 33 - Related articles - BL Direct - All 5 versions
RR Rubin, WY Fujimoto, DG Marrero, T … - Controlled clinical trials, 2002 - ncbi.nlm.nih.gov The Diabetes Prevention Program (DPP) is a multicenter randomized controlled
trial designed to test whether diet and exercise or medication can prevent or
delay the onset of type 2 diabetes in persons with impaired glucose ... Cited by 49 - Related articles
